← Back to Clinical Trials
Recruiting NCT07610356

NCT07610356 Predictors of Transmural Non-Occlusive Mesenteric Ischemia in ICU Patients With Suspected Acute Mesenteric Ischemia

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07610356
Status Recruiting
Phase
Sponsor University of Tartu
Condition Non-Occlusive Mesenteric Ischaemia (NOMI)
Study Type OBSERVATIONAL
Enrollment 150 participants
Start Date 2022-06-06
Primary Completion 2026-06-05

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Observation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 150 participants in total. It began in 2022-06-06 with a primary completion date of 2026-06-05.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Acute mesenteric ischemia (AMI) is a rare but life-threatening condition associated with high mortality and major diagnostic challenges due to nonspecific clinical presentation and limited reliable biomarkers. Critically ill patients in the intensive care unit (ICU) are at particularly high risk of non-occlusive mesenteric ischemia (NOMI), a subtype of AMI characterized by impaired mesenteric perfusion without large-vessel occlusion. Despite advances in imaging, the diagnosis of NOMI remains difficult, and data specifically focusing on ICU patients with suspected AMI are limited. This prospective observational multicenter study aims to identify independent predictors of transmural NOMI among ICU patients with suspected AMI. In addition, the study will describe demographics, comorbidities, clinical presentation, laboratory findings, diagnostic imaging, management strategies, and outcomes among ICU patients with NOMI, other forms of AMI, and patients with suspected but unconfirmed AMI. Consecutive adult ICU patients in whom clinical suspicion of AMI arises during ICU stay will be included across Estonian regional hospitals. The study is a local continuation of the international AMESI study, with a specific focus on critically ill ICU patients.

Eligibility Criteria

Inclusion criteria \- Adult ICU patients in whom clinical suspicion of acute mesenteric ischemia is raised during their ICU stay. Exclusion criteria * Patients who develop acute mesenteric ischemia outside of the intensive care unit, * Confirmed strangulating bowel obstruction, * Individuals younger than 18 years, * Chronic mesenteric ischemia without an acute event.

Frequently Asked Questions

Who can join the NCT07610356 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Non-Occlusive Mesenteric Ischaemia (NOMI). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07610356 currently recruiting?

Yes, NCT07610356 is actively recruiting participants. Visit ClinicalTrials.gov or contact University of Tartu to inquire about joining.

Where is the NCT07610356 trial being conducted?

This trial is being conducted at Tallinn, Estonia, Tartu, Estonia.

Who is sponsoring the NCT07610356 clinical trial?

NCT07610356 is sponsored by University of Tartu. The trial plans to enroll 150 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology